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INTRODUCTION 
Non-steroidal anti-inflammatory drugs (NSAIDs) provide sev-
eral benefits in intraocular and refractive surgery. Because 
NSAIDs are potent inhibitors of cyclooxygenase (COX) en-
zymes, they inhibit production of pro-inflammatory prosta-
glandins, which cause vasodilation and increased vascular 
permeability.1 Therefore, NSAIDs are used to maintain pupil-
lary dilation during surgery, to reduce postoperative pain, to 
control inflammation during and after surgery, and to inhibit 
development of cystoid macular edema (CME) after cataract 
surgery.2-4 
Topical NSAID eye drops gained attention as an alternative 
treatment to topical steroids for postoperative pain and inflam-
mation because they are associated with fewer complications, 
such as increased intraocular pressure, infection, and delayed 
corneal epithelial wound healing.5-8 Concurrent administra-
tion of corticosteroids and NSAIDs has shown potential syner-
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Purpose: To compare the additive effects of two types of non-steroidal anti-inflammatory drugs (NSAIDs), bromfenac 0.1% or ke-
torolac 0.45%, relative to topical steroid alone in cataract surgery. 
Materials and Methods: A total 91 subjects scheduled to undergo cataract operation were randomized into three groups: Group 
1, pre/postoperative bromfenac 0.1%; Group 2, pre/postoperative preservative-free ketorolac 0.45%; and Group 3, postoperative 
steroid only, as a control. Outcome measures included intraoperative change in pupil size, postoperative anterior chamber in-
flammation control, change in macular thickness and volume, and ocular surface status after operation. 
Results: Both NSAID groups had smaller intraoperative pupil diameter changes compared to the control group (p<0.05). There 
was significantly less ocular inflammation 1 week and 1 month postoperatively in both NSAID groups than the control group. The 
changes in central foveal subfield thickness measured before the operation and at postoperative 1 month were 4.30±4.25, 4.87±6.03, 
and 12.47±12.24 μm in groups 1 to 3, respectively. In the control group, macular thickness and volume increased more in patients 
with diabetes mellitus (DM), compared to those without DM. In contrast, in both NSAID groups, NSAIDs significantly reduced 
macular changes in subgroups of patients with or without DM. Although three ocular surface parameters were worse in group 1 
than in group 2, these differences were not significant. 
Conclusion: Adding preoperative and postoperative bromfenac 0.1% or ketorolac 0.45% to topical steroid can reduce intraopera-
tive miosis, postoperative inflammation, and macular changes more effectively than postoperative steroid alone.
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gistic activity in some studies.5,9,10 Food and Drug Administra-
tion (FDA)-approved NSAIDs currently used for cataract surgery 
include diclofenac, ketorolac, nepafenac, and bromfenac.5 
Bromfenac sodium 0.1% ophthalmic solution (Bronuck®, 
Senju Pharmaceutical Co., Ltd., Osaka, Japan) has clinical in-
dications for treating postoperative inflammation, blepharitis, 
conjunctivitis, and scleritis.5 Preservative-free ketorolac 0.45% 
solution (Acuvail®, Allergan Inc., CA, USA) is also targeted for 
postoperative use after cataract surgery.11 
Several reports identified corneal complications of using 
early-generation topical NSAIDs, including corneal melting 
caused by the generic form of diclofenac, as well as ketorolac 
and nepafenac; these reports prompted subsequent decline 
in the use of topical NSAIDs after ocular surgery.12,13 However, 
Flach13 demonstrated that not only simple drug toxicity but 
also coexistent factors, such as concurrent ocular and system-
ic disease, inconsistent and variable doses, and other medica-
tions used simultaneously, were attributable to corneal melt-
ing. Since then, many clinical trials have established the efficacy 
and safety of other topical NSAIDs14,15 and they are being used 
again in ophthalmic surgery. 
In this study, we report the results of a prospective, random-
ized clinical trial that compared two kinds of NSAID eye drops, 
with different application schedules, for use in combination 
therapy with topical steroid for cataract surgery. 
MATERIALS AND METHODS
This single-center, randomized study was approved by the Sev-
erance Hospital Institutional Review Board, Seoul, South Ko-
rea. Participants consisted of 91 patients who were scheduled 
for cataract surgery between November 2013 and June 2014. 
All patients gave written informed consent before enrollment, 
and clinical research was performed in accordance with the 
tenets of the Helsinki Declaration.
Inclusion criteria for enrollment were as follows: males or 
non-pregnant females aged between 20- to 80-years-old. Ex-
clusion criteria were as follows: poor general condition, in-
cluding high blood pressure, poor blood glucose control, or 
renal failure; history of ocular trauma or disease; history of in-
traocular surgery; systemic or topical NSAIDs or corticoste-
roids use within 4 weeks of enrollment; known hypersensitivi-
ty to salicylates or other NSAIDs; and use of alpha-1 adrenergic 
antagonist or other analogous systemic medications that may 
increase the tendency for miosis during the operation (intraop-
erative floppy iris syndrome).
Patients were enrolled in the study during a preoperative 
visit after initial screening. Preoperatively, all patients under-
went a complete ophthalmic examination, including visual 
acuity, slit-lamp examination, indirect ophthalmoscopy, and 
optical coherence tomography (OCT). Patients were random-
ized into three groups according to the administered study drugs, 
and the study medications were masked to both the surgeon 
and examiners. The administration of the topical NSAIDs was 
determined based on the suggested regimen of each pharma-
ceutical company. Group 1 patients were instructed to apply 1 
drop of bromfenac sodium hydrate ophthalmic solution 0.1% 
twice daily beginning 3 days before surgery and two drops at 
20 minute intervals at 2 hours before surgery. They continued 
using bromfenac 0.1% twice-daily with other postoperative 
eye drops for 4 weeks. Group 2 patients were instructed to in-
still 1 drop of ketorolac 0.45% ophthalmic solution twice-daily 
beginning 1 day prior to cataract surgery and 2 drops at 20 
minute intervals at 2 hours before surgery, with continued ap-
plication twice-daily throughout the first 2 postoperative weeks. 
Control eyes in Group 3 did not receive any additional medi-
cations. Postoperatively, patients in all three groups were pre-
scribed topical gatifloxacin 0.3% and prednisolone acetate 1% 
eye drops that were to be applied 4 times daily for 4 weeks. 
Surgical technique 
All cataract surgeries were phacoemulsification with intraoc-
ular lens (IOL) implantation after topical anesthesia with pro-
paracaine hydrochloride 0.5% eye drops by a single surgeon 
(T.I. Kim). The surgical procedure consisted of a clear cornea 
incision on the steep axis, capsulorrhexis, phacoemulsification, 
and IOL placement in the capsular bag. 
Outcome measures
Outcome measures comprised changes in pupil size during sur-
gery, postoperative anterior chamber inflammation, macular 
thickness and volume, and change in the ocular surface status. 
Patients were evaluated on postoperative days 1, 7, and 28. Hori-
zontal pupillary diameters were measured in 0.5 mm units us-
ing a sterile caliper over the cornea and measurements were 
taken under a microscope upon the initiation of the surgery 
and before the insertion of the ophthalmic viscosurgical de-
vice (OVD) for IOL implantation. Ocular inflammation was as-
sessed, and the summed ocular inflammation score (SOIS) was 
calculated by adding the subject’s anterior chamber cells and 
flare grades (range, 0–4) at 1 week and 1 month postoperatively.16 
All OCT images were obtained using the Spectralis SD-OCT 
(Heidelberg Engineering, Carlsbad, CA, USA), and the macu-
lar retinal thickness and volume map analysis protocol was 
used to evaluate the macular state.17 The central foveal sub-
field (CSF) thickness was defined as the average of all points 
in the inner circle within 1 mm radius from the fovea, and mac-
ular thickness was determined as the average thickness of five 
subfields, including the CSF and nasal, temporal, superior, 
and inferior inner segments in the central 3 mm area. We used 
the term macular edema (ME) to describe an increase in mac-
ular thickness or volume of >30% on OCT, 1 month after cata-
ract surgery.18 CME was defined as presence of cystoid chang-
es associated with substantial (≥40 μm) retinal thickening.19 
Evaluation of ocular surface status, including Schirmer test 
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without anesthesia, tear breakup time (TBUT), and fluoresce-
in corneal staining (range, 0–5),20 was performed preoperatively 
and 1 month postoperatively. Adverse events were monitored 
and recorded. 
Statistical analysis 
The results are presented as mean±SD, or as patient number 
and percentage. Comparisons of the outcome measures among 
patient groups were performed using one-way analysis of vari-
ance with Scheffé’s test. Comparisons between the preopera-
tive and postoperative data were analyzed by Wilcoxon rank-
sum tests. Statistical analyses were performed using SPSS 
statistical software (version 20.0; SPSS Inc., Chicago, IL, USA), 
and p-values less than 0.05 were considered statistically sig-
nificant. 
RESULTS 
A total of 91 eyes from 91 subjects (41 men and 50 women) were 
included in the study, and all patients underwent uncompli-
cated phacoemulsification with IOL implantation. Mean age 
of the subjects was 66.9±8.5 years (range, 33–78 years). Table 1 
shows the demographics and preoperative characteristics of 
subjects in all three groups. Overall, baseline demographics 
and clinical characteristics, including preoperative ocular sur-
face status and macular thickness and volume, were similar 
among the groups. There were 24 subjects (26.4%) with diabe-
tes mellitus (DM) without retinopathy. 
Maintenance of pupil dilation during the cataract 
surgery
In group 1, pupil diameters at the beginning of surgery were 
larger than those of Groups 2 and 3 (p=0.043 and 0.046, respec-
tively). Pupil diameters before inserting the OVD for IOL im-
plantation were significantly different between Groups 1 and 
3 (p=0.003). Both NSAID groups (Groups 1, 2) showed small 
decreases in pupil diameter during the surgical procedure, 
compared with Group 3 (p=0.025 and 0.013, respectively) (Table 
2). However, there was no difference in pupil diameter change 
between Group 1 and Group 2. No patients required intraop-
erative additive medication for pupil dilation, such as intracam-
Table 1. Demographics and Preoperative Characteristics of Subjects
Bromfenac 0.1%  
Group 1
Ketorolac 0.45%  
Group 2
Control  
Group 3
p value*
No. of eyes 28 32 31
Sex (M:F) 13:15 15:17 13:18
Hypertension (yes) 11 (39.3%) 12 (37.5%) 11 (35.5%)
Diabetes mellitus (yes) 7 (25.0%) 9 (28.1%) 8 (25.8%)
Age (range) (yr) 66.9±11.1 67.5±7.0 66.8±8.1 0.973
Macular thickness and volume
 CSF thickness (μm) 270.67±21.62 265.80±24.86 265.60±24.79 0.648
 Macular thickness (μm) 317.11±17.55 318.85±13.46 316.62±20.45 0.873
 Macular volume (mm3) 8.50±0.58 8.57±0.30 8.51±0.43 0.534
Ocular surface status
 Schirmer score (mm) 10.7±5.6 9.9±5.1 10.6±6.5 0.892
 Corneal staining (Oxford scheme) 0.5±0.5 0.6±0.5 0.5±0.5 0.762
 TBUT (sec) 6.2±2.7 6.1±2.1 6.5±2.6 0.907
CSF, central foveal subfield; TBUT, tear break-up time.
*Using one-way analysis of variance with Scheffé’s test.
Table 2. Mean Horizontal Diameter of Pupil at the Beginning of Cataract Surgery and before Insertion of the OVD for IOL Implantation after Removal of 
Lens
 Bromfenac 0.1%  
Group 1
Ketorolac 0.45%  
Group 2
Control  
Group 3
p value*
Bromfenac 0.1% vs. 
controls
Ketorolac 0.45% vs. 
controls
Bromfenac 0.1% vs. 
ketorolac 0.45% 
Pupil diameter at the 
  beginning of surgery 
8.58±0.73 7.95±0.69 7.98±0.67 0.043 0.987 0.046
Pupil diameter before insertion 
  of OVD for IOL implantation
8.34±0.83 7.73±0.62 7.36±0.74 0.003 0.235 0.156
Change in pupil diameter -0.24±0.45 -0.23±0.44 -0.62±0.39 0.025 0.013 0.749
OVD, ophthalmic viscosurgical device; IOL, intraocular lens.
*Using one-way analysis of variance with Scheffé’s test.
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eral epinephrine. 
Postoperative anterior chamber inflammation after 
cataract surgery 
One week after surgery, the total scores of cells and flare, SOISs, 
were 0.53±0.61, 0.58±0.69, and 1.74±0.81 in Group 1, 2, and 3, 
respectively. This score was similar (p=0.974) and significantly 
lower in both NSAID groups compared with controls (p<0.001 
in both comparisons). The inflammatory score at 1 month was 
similar in Group 1 and Group 2 (0.21±0.42 and 0.32±0.48, re-
spectively; p=0.853). In contrast, the SIOS of Group 3 was 0.84± 
0.76 at 1 month, which was significantly higher than that for 
both NSAID groups (p=0.005, 0.024, respectively) (Fig. 1). 
Postoperative macular edema after cataract surgery 
Mean CSF, macular thickness, and macular volume significant-
ly increased after cataract operation in all groups (p<0.05 for 
all groups). The CSF thickness increased from before the opera-
tion to postoperative 1 month by 4.30±4.25, 4.87±6.03, and 
12.47±12.24 μm in Groups 1, 2, and 3, respectively. Both NSAID 
groups showed similar increases in CSF thickness, which were 
significantly less than the control group (p<0.05 for both com-
parisons). Increased macular thickness of both NSAID groups 
was significantly less than that in the controls (p<0.05 for both 
comparisons). The total macular volume increased by 0.13± 
0.17, 0.20±0.14, and 0.26±0.19 mm3 in Group 1, 2, and 3, respec-
tively, one month after the operation. A significant difference 
in macular volume existed between the bromfenac 0.1% group 
and the control (Table 3). No eyes in any group exhibited ME 
or CME at 1 month after operation. 
Fig. 2 shows that the macular changes after cataract opera-
tion were different between subgroups according to the pres-
ence of DM. In NSAID-treated Groups 1 and 2, the changes in 
CSF thickness, macular thickness, and macular volume before 
the operation and at postoperative 1 month were not signifi-
cantly different between patients without DM and those with 
DM (p>0.05). However, in Group 3, the changes in CSF thick-
ness were 7.60±6.43 μm in patients without DM and 22.20± 
15.42 μm in patients with DM (p=0.001). The changes in mac-
ular thickness were 9.40±3.75 μm in patients without DM and 
17.30±10.94 μm in patients with DM (p=0.006) and the chang-
es in macular volume were 0.19±0.12 mm3 in patients without 
DM and 0.40±0.25 mm3 in patients with DM (p=0.003). 
Postoperative ocular surface status after cataract 
surgery 
At 1 month postoperatively, TBUT was significantly worse than 
that before cataract surgery in all groups (p<0.05). Although 
all three parameters, especially corneal staining, were worse in 
the bromfenac 0.1% group than the ketorolac 0.45% group, 
these differences were not significant (Table 4). 
 
DISCUSSION 
Several topical NSAIDs are currently approved for controlling 
postoperative inflammation after cataract surgery. Ophthal-
mic NSAID eye drops maintain pupil dilation, reduce postop-
erative inflammation, pain and discomfort, and prevent and 
treat ME after cataract operation.5 Each type of NSAID oph-
thalmic solutions has its own characteristics, thus treatment ef-
fects may differ among various drugs. The purpose of this pro-
spective study was to compare the effects of two different 
Table 3. Comparison of Changes in Macular Retinal Thickness and Volume after Cataract Operation between Groups
Bromfenac 0.1%  
Group 1
Ketorolac 0.45%  
Group 2
Control  
Group 3
p value†
Bromfenac 0.1% vs. 
controls
Ketorolac 0.45% vs. 
controls
Bromfenac 0.1% vs. 
ketorolac 0.45% 
Change of CSF thickness (μm)
  (p value*)
4.30±4.25 
(<0.001)
4.87±6.03 
(<0.001)
12.47±12.24 
(<0.001)
0.010 0.014 0.976 
Change of macular thickness (μm) 
  (p value*)
6.58±6.23 
(<0.001)
5.81±5.04 
(<0.001)
12.03±7.79 
(<0.001)
0.008 0.002 0.905 
Change of macular volume (mm3) 
  (p value*)
0.13±0.17 
(<0.001)
0.20±0.14  
(<0.001)
0.26±0.19 
(0.005)
0.022 0.368 0.363 
CSF, central foveal subfield.
*Using paired t-test statistical analyses, †Using one-way analysis of variance with Scheffé’s test.
Fig. 1. Comparison of summed ocular inflammation score (SOIS) between 
three groups at 1 week and 1 month after cataract surgery. The SOIS was 
sum of the scores of cells and flare16 (maximum possible total score=8). 
This score was significantly lower in both NSAID groups compared with 
the control (p<0.05), but it did not differentiate group 1 from group 2 
(p>0.05). NSAID, non-steroidal anti-inflammatory drug.
4
2
0
1 week
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IS
p<0.001
Bromfenac 0.1%               Ketorolac 0.45%               Control
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NSAIDs with different application schedules, when added to 
concurrent steroid treatment.
Two NSAID ophthalmic solutions, bromfenac sodium hy-
drate 0.1% with 0.005% benzalkonium chloride (BAK) and pre-
servative-free ketorolac tromethamine 0.45% have recently 
become indicated for the control of postoperative inflamma-
tion in people undergoing cataract surgery in Korea. The anti-
inflammatory effect of twice-daily bromfenac sodium 0.1% 
has been reported,2,4,21 and twice-daily administered preser-
vative-free ketorolac 0.45% was well-tolerated and effectively 
treated inflammation and pain after cataract surgery.11 
Additive use of both NSAID eye drops effectively maintained 
pupillary dilation during the operation and reduced postop-
erative ocular inflammation in this study, compared to the ste-
roid-only control group. Previous studies reported that NSAIDs 
potentiate concomitant topical steroid effects of postoperative 
ocular inflammation5,9 and inhibit miosis during the opera-
tion,22,23 as in our results. One difference between previous re-
ports22,23 and ours was the results of preoperative pupil size. 
Since bromfenac sodium 0.1% was used prior to 3 days before 
surgery in Group 1, preoperative pupil size might be larger than 
in other groups. However, because we did not measure pupil 
size before the use of the medication, we cannot conclude this 
definitely. 
In this study, although macular thickness and volume in-
creased in all groups after cataract operation, no patient pre-
sented with clinically important ME or CME during the 1 
month postoperative follow-up period. A previous study24 has 
demonstrated that topical NSAID treatment was effective in 
prevention or treatment of ME or CME after cataract surgery. 
In our study, topical NSAIDs added to corticosteroid also re-
duced these changes more effectively than corticosteroid 
alone. Spectralis OCT has a very high repeatability and repro-
ducibility, with a very small measurable change (1.5 μm) and 
coefficient of variation (0.53%);25 therefore, small changes and 
differences between groups in our study can be considered as 
meaningful findings. 
A randomized study by Wittpenn, et al.19 reported that a com-
bination of ketorolac 0.4% and steroid, compared to steroid 
alone, reduced CME incidence rate (0.0% versus 2.4%) and 
postoperative mean retinal thickening (3.9 μm versus 9.6 μm) 
in cataract surgery patients. Our results demonstrated the ef-
fects of NSAIDs on ME after cataract surgery in patients with-
out DM and in early phase of DM patients without retinopa-
thy (24/91, 26.4% of total patients). In the control group, CSF, 
macular thickness, and macular volume significantly in-
creased after cataract procedure in the subgroup of patients 
with DM. In contrast, in both NSAIDs groups, macular chang-
es were minimized in both subgroups with DM or without 
DM. Diabetic patients who have no diabetic retinopathy or 
definite ME show partial damage to the blood-retinal barrier.26 
Prostaglandins released by surgical trauma cause vasodila-
tion, increased vascular permeability, and breakdown of the 
blood-retinal barrier, and consequently, postoperative ME or 
CME can potentially develop.27 Thus, prophylactic treatment 
of topical NSAIDs would be recommended in DM patients with 
a weak barrier, even if they do not exhibit diabetic retinopathy.
There was no superiority between two NSAID ophthalmic 
solutions in inhibiting miosis and reducing inflammation and 
macular change. Topical NSAIDs inhibit ocular COX-1 and 
Fig. 2. Comparison of changes in central foveal subfield thickness (A), 
macular thickness (B), and macular volume (C) using Spectralis optical 
coherence tomography after cataract operation between subgroups of 
patients without or with diabetes mellitus (DM). In group 3, changes in 
central foveal subfield (CSF) thickness, macular thickness, and macular 
volume measured before operation and at 1 month postoperatively were 
significantly different between patients without DM and those with DM 
(p>0.05). The changes in CSF thickness, macular thickness, and macular 
volume measured before operation and at 1 month postoperatively were 
not significantly different between patients without DM and those with 
DM in group 1, 2 (p>0.05). 
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COX-2 enzyme activities, thereby reducing prostaglandin pro-
duction and providing both analgesic and anti-inflammatory 
effects. One report demonstrated that administration of ke-
torolac 0.4% four times a day may provide better control of 
prostaglandin-mediated inflammation than administration of 
bromfenac 0.09% twice a day, by showing the inhibition of 
prostaglandin E2 in aqueous level.28 Meanwhile, other studies 
reported that ketorolac inhibited COX-1 more strongly, while 
bromfenac had greater COX-2 inhibitory activity than ketoro-
lac.5,29,30 Because COX-2 is the primary mediator of ocular in-
flammation, COX-2 inhibitory activity is thought to be more 
critical. Our study compared for the first time, the clinical ef-
fects of two NSAID eye drops administered with the same fre-
quency and at different durations of application based on 
manufacturer suggested guidelines, and found no significant 
differences in effectiveness between these two NSAID regi-
mens. The use of ketorolac 0.45% for 2 weeks showed compa-
rable effects in controlling inflammation to the use of bromfe-
nac 0.1% for 4 weeks. 
Acuvail® (ketorolac 0.45%) contains no BAK and contains car-
boxy-methylcellulose, which preserves ocular surface stability 
and promotes corneal reepithelialization.12,31 The BAK in Bro-
nuck® (bromfenac 0.1%) is 0.005%, which is as low as or lower 
than that in other commercially available preserved ophthal-
mic eye drops. The eyes in the bromfenac 0.1% group showed 
worsening of the ocular surface, especially corneal staining, 
than those of the ketorolac group, although this difference did 
not achieve statistical significance. BAK has been shown to 
cause delays in epithelial wound healing due to increase in in-
flammation and trans-epithelial permeability, as well as de-
creases in epithelial vitality.15,32-34 Therefore, although we ex-
pected to observe a difference in change in ocular surface 
status between the two NSAIDs groups, we did not. The possi-
ble reasons for this may be related to the relatively short-term 
and twice per day application or use of a low BAK concentra-
tion of bromfenac 0.1%. There were no adverse events except 
for a mild burning sensation in one patient in the ketorolac 
group; the symptom was tolerable and did not lead to discon-
tinuation of the medication. 
This study had several limitations, including its relatively 
small sample size, which limited the statistical power. Because 
the follow-up time was only 1 month, late onset CME patients 
were not detected. 
In conclusion, we believe that combination therapy of a top-
ical steroid and bromfenac 0.1% or ketorolac 0.45% NSAID 
ophthalmic solution for cataract surgery is superior to steroid 
alone in suppressing intraoperative miosis, ocular inflamma-
tion, and macular changes after cataract operation.
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